Published in Med Sci Monit on January 03, 2016
Immunity, inflammation, and cancer. Cell (2010) 28.27
A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest (2007) 8.54
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer (2004) 4.43
Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res (2006) 2.37
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol (2008) 2.27
Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One (2010) 1.92
High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med (2014) 1.91
IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol (2014) 1.89
Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care (2005) 1.73
Effects of oral vitamin C supplementation on oxidative stress and inflammation status in haemodialysis patients. Nephrol Dial Transplant (2005) 1.61
The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care (2009) 1.52
IL-2 gene expression and NF-kappa B activation through CD28 requires reactive oxygen production by 5-lipoxygenase. EMBO J (1995) 1.47
Reevaluation of ascorbate in cancer treatment: emerging evidence, open minds and serendipity. J Am Coll Nutr (2000) 1.37
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One (2012) 1.35
Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene (2014) 1.30
Cytokines in cancer immunotherapy. Cancers (Basel) (2011) 1.26
Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol (2000) 1.26
Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med (2012) 1.09
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J (2005) 1.08
Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol (2013) 1.07
Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci (2007) 1.04
Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer (2001) 1.02
Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci (2007) 1.01
Regulatory T cells interfere with glutathione metabolism in dendritic cells and T cells. J Biol Chem (2010) 1.01
High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med (2009) 1.00
Low ascorbate levels are associated with increased hypoxia-inducible factor-1 activity and an aggressive tumor phenotype in endometrial cancer. Cancer Res (2010) 0.99
Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal (2013) 0.97
Plasma C-reactive protein concentrations in active and passive smokers: influence of antioxidant supplementation. J Am Coll Nutr (2004) 0.94
Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits IkappaBalpha kinase beta. Mol Cell Biol (2004) 0.94
Vitamin C inhibits granulocyte macrophage-colony-stimulating factor-induced signaling pathways. Blood (2002) 0.93
Immune function in aged women is improved by ingestion of vitamins C and E. Can J Physiol Pharmacol (1998) 0.93
Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med (2008) 0.92
Effects of vitamin C on intracytoplasmic cytokine production in human whole blood monocytes and lymphocytes. Cytokine (2004) 0.90
Ascorbic acid uptake and regulation of type I collagen synthesis in cultured vascular smooth muscle cells. J Vasc Res (2008) 0.88
Cytokine regulation networks in the cancer microenvironment. Front Biosci (2008) 0.88
Review of high-dose intravenous vitamin C as an anticancer agent. Asia Pac J Clin Oncol (2014) 0.87
Induction of an inflammatory loop by interleukin-1β and tumor necrosis factor-α involves NF-kB and STAT-1 in differentiated human neuroprogenitor cells. PLoS One (2013) 0.86
Effect of ascorbic acid on microcirculation in patients with Type II diabetes: a randomized placebo-controlled cross-over study. Clin Sci (Lond) (2005) 0.86
Long-term combined supplementations with alpha-tocopherol and vitamin C have no detectable anti-inflammatory effects in healthy men. J Nutr (2003) 0.85
NF-κB functions in tumor initiation by suppressing the surveillance of both innate and adaptive immune cells. Cell Rep (2014) 0.84
Vitamin C promotes maturation of T-cells. Antioxid Redox Signal (2013) 0.84
Vascular endothelium and inflammatory process, in patients with combined Type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C. Diabet Med (2004) 0.84
Vitamin C supplementation modulates gene expression in peripheral blood mononuclear cells specifically upon an inflammatory stimulus: a pilot study in healthy subjects. Genes Nutr (2014) 0.81
Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy. PLoS Negl Trop Dis (2012) 0.81
Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma. Med Sci Monit (2013) 0.79
Cytokine networks that mediate epithelial cell-macrophage crosstalk in the mammary gland: implications for development and cancer. J Mammary Gland Biol Neoplasia (2014) 0.78
Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon-α but Not Observation in Intermediate Risk Melanoma Patients. PLoS One (2015) 0.78
[Tumor microenvironment: regulatory cells and immunosuppressive cytokines]. Med Sci (Paris) (2014) 0.76